Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape.
Familial adenomatous polyposis (FAP) or classic FAP is a genetic condition that causes extra tissue (polyps) to form in large intestine and rectum. It is caused by germline mutations in the APC gene. Symptoms include blood or mucus in the stools, diarrhea or constipation, weight loss due to unknown reason and abdominal pain. Treatment includes surgery and medications (NSAIDs).
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Familial Adenomatous Polyposis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Familial Adenomatous Polyposis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 2, 4, 9, 1 and 1 respectively.
Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Familial Adenomatous Polyposis (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Familial Adenomatous Polyposis (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Familial Adenomatous Polyposis (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Familial Adenomatous Polyposis (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Familial Adenomatous Polyposis - Overview
Familial Adenomatous Polyposis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Familial Adenomatous Polyposis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Familial Adenomatous Polyposis - Companies Involved in Therapeutics Development
ADT Pharmaceuticals Inc
Cancer Prevention Pharmaceuticals Inc
Cellix Bio Pvt Ltd
DNAlite Therapeutics Inc
Eloxx Pharmaceuticals Inc
Emtora Biosciences
FunPep Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
KD Pharma Group SA
Recursion Pharmaceuticals Inc
SanaRx Biotherapeutics Inc
Stemsynergy Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
TherapyX Inc
Thetis Pharmaceuticals LLC
Familial Adenomatous Polyposis - Drug Profiles
(eflornithine hydrochloride + sulindac) - Drug Profile
Product Description
Mechanism Of Action
History of Events
CLXONC-575 - Drug Profile
Product Description
Mechanism Of Action
FAPXIL SR - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Familial Adenomatous Polyposis - Drug Profile
Product Description
Mechanism Of Action
guselkumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
icosapent ethyl - Drug Profile
Product Description
Mechanism Of Action
History of Events
interleukin-10 SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
lorpucitinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
magnesium lysinate bis eicosapentaenoate - Drug Profile
Product Description
Mechanism Of Action
History of Events
ombipepimut-s - Drug Profile
Product Description
Mechanism Of Action
History of Events
pyrvinium pamoate - Drug Profile
Product Description
Mechanism Of Action
History of Events
REC-4881 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SB-201 - Drug Profile
Product Description
Mechanism Of Action
SHR-1020 - Drug Profile
Product Description
Mechanism Of Action
sirolimus - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Familial Adenomatous Polyposis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit PDE10 for Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Synthetic peptide for Familial Adenomatous Polyposis - Drug Profile
Product Description
Mechanism Of Action
History of Events
ZKN-013 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Familial Adenomatous Polyposis - Dormant Projects
Familial Adenomatous Polyposis - Discontinued Products
Familial Adenomatous Polyposis - Product Development Milestones
Featured News & Press Releases
Oct 12, 2021: Flynpovi: Withdrawal of the marketing authorisation application
Sep 29, 2021: Recursion is granted orphan drug designation for REC-4881 for the potential treatment of familial adenomatous polyposis
Jul 23, 2021: Cancer Prevention Pharmaceuticals has requested a re-examination of EMA’s June 2021 opinion on Flynpovi
Jun 25, 2021: CHMP adopted a negative opinion on the marketing authorisation application for Flynpovi
Sep 11, 2020: Cancer Prevention Pharmaceuticals Announces NEJM publication of landmark phase 3 clinical trial for treatment of familial adenomatous polyposis
Jun 29, 2020: Cancer Prevention Pharmaceuticals submits New Drug Application to the FDA for CPP-1X/sul for treatment of familial adenomatous polyposis
Jun 18, 2020: Cancer Prevention Pharmaceuticals submits EU marketing authorization application for CPP-1X/sul for treatment of familial adenomatous polyposis
Apr 15, 2020: KD Pharma and SLA Pharma to study EPAspire for Covid-19
Nov 17, 2019: National Institute of Diabetes and Digestive and Kidney Diseases awards $2,073,687 SBIR fasttrack grant to Therapyx
Aug 26, 2019: Emtora Biosciences awarded $3 million CPRIT grant to study efficacy of eRapa in familial adenomatous polyposis
Aug 01, 2019: SLA Pharma announces meeting with the FDA in October 2019 for ALFA
Jun 20, 2019: Cancer Prevention Pharmaceuticals (CPP) reports FAP phase 3 clinical trial results at Digestive Disease Week Conference
May 07, 2019: Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt announce results from pivotal phase 3 trial of CPP-1X/Sulindac in patients with familial adenomatous polyposis
Apr 15, 2019: MorphoSys announces that its licensee Janssen has expanded clinical development of Guselkumab (Tremfya) into familial adenomatous polyposis
Feb 26, 2019: Rapamycin Holdings rebrands to Emtora Biosciences as new leadership focuses company on next steps
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Familial Adenomatous Polyposis, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Familial Adenomatous Polyposis - Pipeline by ADT Pharmaceuticals Inc, 2022
Familial Adenomatous Polyposis - Pipeline by Cancer Prevention Pharmaceuticals Inc, 2022
Familial Adenomatous Polyposis - Pipeline by Cellix Bio Pvt Ltd, 2022
Familial Adenomatous Polyposis - Pipeline by DNAlite Therapeutics Inc, 2022
Familial Adenomatous Polyposis - Pipeline by Eloxx Pharmaceuticals Inc, 2022
Familial Adenomatous Polyposis - Pipeline by Emtora Biosciences, 2022
Familial Adenomatous Polyposis - Pipeline by FunPep Co Ltd, 2022
Familial Adenomatous Polyposis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Familial Adenomatous Polyposis - Pipeline by Johnson & Johnson, 2022
Familial Adenomatous Polyposis - Pipeline by KD Pharma Group SA, 2022
Familial Adenomatous Polyposis - Pipeline by Recursion Pharmaceuticals Inc, 2022
Familial Adenomatous Polyposis - Pipeline by SanaRx Biotherapeutics Inc, 2022
Familial Adenomatous Polyposis - Pipeline by Stemsynergy Therapeutics Inc, 2022
Familial Adenomatous Polyposis - Pipeline by Sumitomo Dainippon Pharma Co Ltd, 2022
Familial Adenomatous Polyposis - Pipeline by TherapyX Inc, 2022
Familial Adenomatous Polyposis - Pipeline by Thetis Pharmaceuticals LLC, 2022
Familial Adenomatous Polyposis - Dormant Projects, 2022
Familial Adenomatous Polyposis - Discontinued Products, 2022
List of Figures
Number of Products under Development for Familial Adenomatous Polyposis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
